JPMorgan Chase & Co. Boosts Stake in Phibro Animal Health Corporation $PAHC

JPMorgan Chase & Co. raised its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 1,730.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 238,115 shares of the company’s stock after acquiring an additional 225,110 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.59% of Phibro Animal Health worth $9,634,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Capricorn Fund Managers Ltd purchased a new stake in shares of Phibro Animal Health during the third quarter valued at about $10,233,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Phibro Animal Health in the 3rd quarter worth approximately $8,931,000. Ranger Investment Management L.P. grew its position in shares of Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares during the last quarter. Millennium Management LLC raised its stake in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares in the last quarter. Finally, Advisors Preferred LLC purchased a new stake in Phibro Animal Health during the third quarter valued at approximately $3,953,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Stock Performance

PAHC opened at $53.88 on Monday. The company has a market cap of $2.18 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 0.83 and a beta of 0.73. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The firm’s 50-day moving average price is $49.06 and its 200-day moving average price is $43.35. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $57.62.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. The company had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were issued a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is 21.33%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PAHC. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $52.52, for a total value of $369,740.80. Following the transaction, the chief executive officer directly owned 73,320 shares of the company’s stock, valued at $3,850,766.40. This represents a 8.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 316,800 shares of company stock worth $15,278,569 over the last 90 days. 50.13% of the stock is owned by insiders.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.